Bioabsorbable Nanospheres for Selective T-Cell Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for treating autoimmune disorders, such as Type 1 Diabetes, using antigen vaccination have shown limited success due to the complexity of autoimmunity and the unpredictability of immune responses, requiring multiple epitopes and precise dosing, making peptide therapy impractical and ineffective.
Innovation Solution
Delivery of antigen/MHC complexes on biocompatible, bioabsorbable nanospheres to selectively expand anti-autoimmune CD8+ cells and delete pathogenic cells, preventing autoimmune responses in a tissue-specific manner without causing generalized immunosuppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antigen vaccination is used to treat autoimmune disorders, then T-cell tolerance can be induced, but the treatment fails to achieve reliable clinical success due to the complexity and unpredictability of immune responses
Solution Approach 1:
The patent segments the complex immune response into distinct T-cell populations (pathogenic vs. protective) and targets them separately using epitope-specific nanospheres. By dividing the treatment approach into discrete epitope-targeted components rather than broad antigen vaccination, the system achieves more predictable and reliable outcomes in autoimmune disease models.
Solution Approach 2:
The invention applies local quality by creating nanospheres with specific epitope-MHC complexes that selectively interact with particular T-cell receptors. This localized specificity allows the treatment to target only pathogenic T-cells while preserving protective immune responses, thereby improving reliability without being overwhelmed by overall immune system complexity.
2Adaptability or versatility
If multiple epitopes and precise dosing are required to address autoimmune complexity, then treatment coverage can be improved, but the therapy becomes impractical and ineffective due to dosing complexity
Solution Approach 1:
The patent merges multiple epitope-MHC complex formulations into a unified nanosphere platform. Rather than requiring separate dosing regimens for each epitope, the system combines them in defined ratios within single nanosphere preparations, simplifying administration while maintaining comprehensive coverage of pathogenic T-cell populations.
Solution Approach 2:
The invention utilizes parameter changes by optimizing the ratio of different epitope-MHC complexes within nanospheres and adjusting nanosphere dosage to achieve therapeutic effects. This approach transforms the complexity of multiple epitope dosing into a simplified protocol based on nanosphere concentration and frequency, making the treatment practical while maintaining versatility.
3Object-affected harmful factors
If broad immune suppression is used to treat autoimmune disease, then autoimmune responses can be reduced, but generalized immunosuppression occurs which is not desirable
Solution Approach 1:
The patent extracts and isolates specific pathogenic T-cell populations from the broader immune system using epitope-specific nanospheres. By removing only the harmful pathogenic components while leaving protective immune mechanisms intact, the treatment reduces autoimmune responses without causing generalized immunosuppression.
Solution Approach 2:
The nanosphere acts as an intermediary that selectively delivers epitope-MHC complexes to pathogenic T-cells. This mediator enables targeted suppression of autoimmune responses while preserving overall immune function, avoiding the harmful effects of broad immunosuppression.
Data Source
AI summary
The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells using biocompatible bioabsorbable nanospheres. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.